Pulmonary Hypertension: Role of Combination Therapy

被引：1
|
作者：
Meis, Tobias [2 ]
Behr, Juergen [1 ]
机构：
[1] Ruhr Univ Bochum, Univ Hosp Bergmannsheil GmbH, Dept Internal Med Resp & Crit Care Med 3, D-44789 Bochum, Germany
[2] Univ Munich, Dept Internal Med 1, Div Resp Dis, D-81377 Munich, Germany
来源：
CURRENT VASCULAR PHARMACOLOGY | 2011年 / 9卷 / 04期
关键词：
Combination therapy; endothelin receptor antagonists; phosphodiesterase-5-inhibitors; prostanoids; pulmonary hypertension; randomized controlled trials; open-label; CONTINUOUS INTRAVENOUS EPOPROSTENOL; SMOOTH-MUSCLE-CELLS; ARTERIAL-HYPERTENSION; INHALED ILOPROST; BOSENTAN THERAPY; CONTROLLED-TRIAL; ORAL SILDENAFIL; DOUBLE-BLIND; EFFICACY; TREPROSTINIL;
D O I：
10.2174/157016111796197242
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Over the past decade different effective treatment options for use in pulmonary arterial hypertension (PAH) have been developed. Due to multiple pathophysiological pathways in PAH and unsatisfactory overall results with the use of monotherapy in a substantial number of PAH patients, there is a pharmacological rationale for combination therapy. The currently approved substances target the prostacyclin, the endothelin and the NO (nitric oxide) -pathways. Those agents have shown a varying degree of improvement in different categories of PAH associated limitations like hemodynamics, exercise capacity, functional class, and quality of life. However, clinical worsening over time is still significant in most patients irrespective of the treatment utilized. The recently published ESC-ERS (European Society of Cardiology and European Respiratory Society) guidelines on pulmonary hypertension suggest the use of combination therapy in patients who do not respond adequately to monotheapy. This article reviews and critically discusses the available data on combination therapy in PAH.
引用
收藏
页码：457 / 464
页数：8
相关论文
共 50 条
  • [21] Combination Therapy with Sildenafil and Sitaxentan for Pulmonary Arterial Hypertension
    Voswinckel, R.
    Gross, N.
    Reichenberger, F.
    Thamm, M.
    Karadas, B.
    Gall, H.
    Nef, H.
    Grimminger, F.
    Seeger, W.
    Ghofrani, H. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [22] Pulmonary arterial Hypertension: Initial Combination Therapy preferred
    不详
    KARDIOLOGE, 2020, 14 (01): : 2 - 2
  • [23] Combination therapy for scleroderma associated pulmonary arterial hypertension
    Kabunga, P.
    Bloore, D.
    Das, C.
    Handler, C.
    Vrapi, F.
    Denton, C.
    Black, C.
    Smith, C.
    Coghlan, J.
    HEART, 2007, 93 : A101 - A102
  • [24] The Role of Combination Therapy in the Treatment of Arterial Hypertension
    Tsareva, V. M.
    Khozyainova, N. Yu.
    KARDIOLOGIYA, 2009, 49 (06) : 15 - 18
  • [25] Melatonin and hypertension: a possible role in combination therapy
    Budnevsky, A. V.
    Ovsyannikov, E. S.
    Rezova, N. V.
    Shkatova, Ya. S.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (12) : 122 - 126
  • [26] The Role of Combination Therapy for Hypertension After ACCOMPLISH
    Lackland D.T.
    Current Cardiovascular Risk Reports, 2010, 4 (4) : 251 - 255
  • [27] The role of riociguat in combination therapies for pulmonary arterial hypertension
    Rahaghi, Franck F.
    Trivieri, Maria Giovanna
    Sahay, Sandeep
    RESPIRATORY MEDICINE, 2023, 211
  • [28] Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension
    Jose, Arun
    Rafei, Hind
    Ahari, Jalil
    PULMONARY CIRCULATION, 2017, 7 (04) : 803 - 807
  • [29] The Role Of Exercise Therapy In Pulmonary Arterial Hypertension
    Mackenzie, A.
    Ford, J.
    Jayasekera, G.
    Pollok, V.
    Crowe, T.
    Peacock, A.
    Church, C.
    Johnson, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [30] Sequential Combination Therapy in a Patient With Idiopathic Pulmonary Arterial Hypertension
    Tsareva, N. A.
    Avdeev, S. N.
    Neklyudova, G. V.
    KARDIOLOGIYA, 2016, 56 (03) : 97 - 100
12345